1. Home
  2. NBTX vs IDE Comparison

NBTX vs IDE Comparison

Compare NBTX & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBTX
  • IDE
  • Stock Information
  • Founded
  • NBTX 2003
  • IDE 2010
  • Country
  • NBTX France
  • IDE United States
  • Employees
  • NBTX N/A
  • IDE N/A
  • Industry
  • NBTX Biotechnology: Pharmaceutical Preparations
  • IDE Finance/Investors Services
  • Sector
  • NBTX Health Care
  • IDE Finance
  • Exchange
  • NBTX Nasdaq
  • IDE Nasdaq
  • Market Cap
  • NBTX 167.8M
  • IDE 163.0M
  • IPO Year
  • NBTX 2020
  • IDE N/A
  • Fundamental
  • Price
  • NBTX $4.10
  • IDE $11.36
  • Analyst Decision
  • NBTX Strong Buy
  • IDE
  • Analyst Count
  • NBTX 1
  • IDE 0
  • Target Price
  • NBTX $8.00
  • IDE N/A
  • AVG Volume (30 Days)
  • NBTX 11.5K
  • IDE 33.5K
  • Earning Date
  • NBTX 04-02-2025
  • IDE 01-01-0001
  • Dividend Yield
  • NBTX N/A
  • IDE 8.83%
  • EPS Growth
  • NBTX N/A
  • IDE N/A
  • EPS
  • NBTX N/A
  • IDE N/A
  • Revenue
  • NBTX N/A
  • IDE N/A
  • Revenue This Year
  • NBTX N/A
  • IDE N/A
  • Revenue Next Year
  • NBTX $221.06
  • IDE N/A
  • P/E Ratio
  • NBTX N/A
  • IDE N/A
  • Revenue Growth
  • NBTX N/A
  • IDE N/A
  • 52 Week Low
  • NBTX $2.76
  • IDE $8.61
  • 52 Week High
  • NBTX $7.29
  • IDE $10.46
  • Technical
  • Relative Strength Index (RSI)
  • NBTX 64.63
  • IDE 72.90
  • Support Level
  • NBTX $3.64
  • IDE $11.21
  • Resistance Level
  • NBTX $4.20
  • IDE $11.33
  • Average True Range (ATR)
  • NBTX 0.16
  • IDE 0.13
  • MACD
  • NBTX 0.04
  • IDE -0.00
  • Stochastic Oscillator
  • NBTX 88.51
  • IDE 83.61

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

Share on Social Networks: